Ahead of Print Issue - March 2021, Volume 15, Issue No. 1

1. Bogdan Y, Tornetta P 3rd, Einhorn TA, Guy P, Leveille L, Robinson J, et al. Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter Retrospective Cohort. J Orthop Trauma. 2016; 30(4): 177-81. doi: 10.1097/BOT.0000000000000516
2. Im GI, Lee SH. Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review. J Bone Metab. 2015; 22(4):183-9. doi: 10.11005/jbm.2015.22.4.183
3. Tsuchie H, Miyakoshi N, Iba K, Kasukawa Y, Nozaka K, Dohke T, et al. The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration. Osteoporos Int. 2018; 29(12): 2659-65. doi: 10.1007/s00198-018-4658-7
4. Starr J, Tay YKD, Shane E. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. Curr Osteoporos Rep. 2018; 16(4): 519-29. doi: 10.1007/s11914-018-0464-6
5. Eastell R, Walsh JS. Anabolic treatment for osteoporosis: teriparatide. Clin Cases Miner Bone Metab. 2017; 14(2): 173-8. doi: 10.11138/ccmbm/2017.14.1.173

Abstract   |   Reference